The fate of drug discovery in academia; dumping in the publication landfill?
Authors:
- Uzma SaqibUSUzma Saqib
- Isaac S. DemareeIDIsaac S. Demaree
- Alexander G. ObukhovAlexander G. Obukhov
- Mirza S. BaigMBMirza S. Baig
- Amiram ArielAAAmiram Ariel
- Krishnan HajelaKHKrishnan Hajela
Open Access
- 6 January 2024
- journal article
- editorial
- Published by Impact Journals, LLC in Oncotarget
- Vol. 15 (1) , 31-34
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- AI in drug discovery and its clinical relevanceHeliyon, 2023
- Inside the nascent industry of AI-designed drugsNature Medicine, 2023
- Why 90% of clinical drug development fails and how to improve it?Acta Pharmaceutica Sinica B, 2022
- Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018JAMA, 2020
- Academia and industry: allocating credit for discovery and development of new therapiesJournal of Clinical Investigation, 2019
- eToxPred: a machine learning-based approach to estimate the toxicity of drug candidatesBMC Pharmacology and Toxicology, 2019
- The Current Status of Drug Discovery and Development as Originated in United States Academia: The Influence of Industrial and Academic Collaboration on Drug Discovery and DevelopmentClinical and Translational Science, 2018
- Drug discovery and development: Role of basic biological researchAlzheimer's & Dementia: Translational Research & Clinical Interventions, 2017
- Drug discovery in academiaExperimental Hematology, 2015
- Academia–industry partnerships in drug discoveryExpert Opinion on Drug Discovery, 2006